Healthcare Global Enterprises Limited (HCG), a leading provider of comprehensive cancer care in India, has announced the appointment of Manu Shankar Das as its new Chief Marketing Officer. The decision was approved by the company's Board of Directors on November 12, 2025, based on the recommendation of the Nomination and Remuneration Committee.

Appointment Details

Das is expected to join HCG on or before December 20, 2025, and will be part of the company's Senior Management Personnel. This strategic appointment comes as HCG continues to strengthen its leadership team and enhance its marketing capabilities.

Extensive Experience

Manu Shankar Das brings over 15 years of cross-industry marketing experience to his new role at HCG. His diverse background spans several sectors, including:

• Healthcare
• Interior Design
• Food & Hospitality
• Travel
• FMCG (Fast-Moving Consumer Goods)
• Information Technology

Areas of Expertise

Das's expertise covers a wide range of marketing disciplines, including:

• Performance marketing
• Brand strategy
• Product marketing
• Digital marketing
• Sales promotions

Professional Background

Prior to joining HCG, Das has held positions at several notable organizations:

• MediBuddy
• Rebbus
• Bonito Designs
• Flavors Unlimited

Additionally, Das has a background as a software engineer, with more than 12 years dedicated to marketing and branding roles.

Strategic Importance

The appointment of Manu Shankar Das as Chief Marketing Officer is expected to bolster HCG's marketing strategies and brand presence in the competitive healthcare sector. His diverse experience across multiple industries may bring fresh perspectives to HCG's marketing initiatives, potentially helping the company to expand its reach and strengthen its position as a leader in cancer care.

As HCG continues to grow its network of comprehensive cancer centers across India and Africa, Das's expertise in performance marketing and digital strategies could play a crucial role in enhancing the company's patient outreach and engagement efforts.

The healthcare industry, particularly in specialized fields like oncology, requires nuanced marketing approaches. Das's background in both healthcare and technology sectors positions him well to navigate the complexities of marketing advanced medical services while maintaining sensitivity to patient needs.

HCG's decision to bring in a marketing professional with such diverse experience signals the company's commitment to innovative marketing strategies in the evolving healthcare landscape. As the new Chief Marketing Officer, Manu Shankar Das will likely be tasked with elevating HCG's brand, driving patient engagement, and supporting the company's mission to make advanced cancer care accessible to a wider population.

Healthcare Global Enterprises Limited (HCG), a leading provider of specialized oncology services in India, has announced its plans to expand its footprint in the African healthcare market. The company's Board of Directors has approved an investment of up to Rs. 700 lakhs (approximately $840,000) in Cancer Care Kenya Limited, a step-down subsidiary of HCG.

Investment Details

The investment, which is subject to applicable regulatory approvals and completion of necessary formalities, will be made in equity shares of Cancer Care Kenya Limited. The decision was made during the Board meeting held on November 12, 2023, and is based on the fair value of Cancer Care Kenya's shares as determined by an independent valuer.

Strategic Expansion

This move appears to be part of HCG's strategy to strengthen its presence in the African healthcare sector. Cancer Care Kenya Limited, which operates in Nairobi, Kenya, provides radiation and chemotherapy services, including a 15-bedded Day Care Centre.

Financial Performance of Cancer Care Kenya

Cancer Care Kenya has shown significant growth in recent years. For the financial year ended March 31, 2023, the company reported:

The company's revenue has shown substantial growth over the past three years:

Market Implications

This investment may signal HCG's confidence in the growth potential of the African healthcare market, particularly in oncology services. It also reflects the company's commitment to expanding its international presence and diversifying its revenue streams.

Regulatory Compliance

The investment is structured in compliance with applicable regulations, including those set by the Securities and Exchange Board of India (SEBI). HCG has stated that the proposed investment is subject to necessary regulatory approvals, indicating the company's adherence to cross-border investment norms.

Multi-Year Growth Strategy

In addition to its investment in Cancer Care Kenya, Healthcare Global Enterprises has outlined a comprehensive multi-year growth strategy. The strategy focuses on:

1. Oncology Expansion: The company plans to invest in new cancer centers across Tier-1 and Tier-2 cities, broadening its reach and service offerings.

2. Clinical Excellence: HCG aims to maintain and enhance its reputation for providing high-quality oncology care.

3. Regional Network Deepening: The strategy includes strengthening HCG's presence in existing markets while expanding into new regions.

4. Margin Improvement: The company expects strong margins, supported by high-occupancy hospitals and operational efficiency measures.

5. Precision Oncology: HCG is emphasizing the development and implementation of precision oncology techniques to improve treatment outcomes.

6. Digital Health Platforms: The company plans to leverage digital health technologies to enhance patient care and operational efficiency.

This multi-faceted approach demonstrates HCG's commitment to long-term growth and its ambition to strengthen its position as a leader in oncology services both in India and internationally.

As Healthcare Global Enterprises continues to expand its operations, the investment in Cancer Care Kenya, coupled with its comprehensive growth strategy, could potentially enhance its position in the growing African healthcare market and contribute to its long-term growth in specialized oncology services.